polymicrobial sepsis (Pseudomonas and Candida spp.) and ventilator-associated pneumonia due to MDR A. baumannii. On the 29 th day following admission, he was started on injection polymyxin B (6 lakh units, 12 th hourly), oral fluconazole (400 mg, Ryles Tube, once daily), and injection meropenem (1 g, 12 hourly). In spite of vigorous medical management, he developed acute kidney injury for which dialysis was started on dopamine 10 μg/kg/min. His hemodynamics and respiratory mechanics did not improve in spite of aggressive medical care. He succumbed to florid sepsis after 37 days of hospitalization.
Yeast identification
Gram-stained smear from the positive blood culture by BacT-ALERT showed oval budding yeast-like cells. Sabouraud dextrose agar (SDA) showed cream-colored colonies, and CHROMagar Candida (HiCrome™ Candida Differential Agar from HiMedia) showed cream colonies with purple tinge after 48 h of incubation. SDA plate incubated at 42°C also grew yeast-like pasty colonies. Carbohydrate fermentation and assimilation tests were carried out with glucose, maltose, lactose, sucrose, galactose, and trehalose, and the results were inconclusive, with only glucose was fermented, and all other carbohydrates were neither fermented nor assimilated. Antifungal susceptibility testing (done on day 32) showed resistance to fluconazole (by disc diffusion), and later, on day 37, sensitivity to echinocandin (by E-strip test, from HiMedia) was tested with MIC of 0.25 μg/mL (susceptible). Two weeks after the death of the patient, isolate was identified as C. auris with nucleic acid sequencing of the ITS and D1/D2 regions of the 28S subunit of the ribosome at the WHO Mycology Reference Laboratory, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
DISCUSSION AND REVIEW OF LITERATURE
C. auris, a new MDR yeast pathogen, was first detected in the external ear canal of a female patient in Tokyo, Japan, in 2009. [3] Hence, it was named as C. auris. It is globally emerging as an MDR yeast that can cause fatal invasive infections. Accurate identification of this organism is possible by DNA sequencing or MALDI-ToF. Laboratories lacking these facilities fail to identify the organism, leading to inadequate treatment of life-threatening infections.
Here, we report a case of C. auris fungemia in a patient with multiple underlying risk factors which included CAP of the right lower and middle lobe of the lung, OSA with chronic type II respiratory failure, hypothyroidism, and morbid obesity. This was compounded with acute kidney the clinical outcome. DNA sequencers or matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) biotypers can help in accurate rapid identification of this MDR yeast. [1] 
CASE REPORT
A 62-year-old male patient presented to this hospital with gradually worsening breathlessness and cough for 2 weeks and right-sided retrosternal nonradiating type of pain with high-grade fever for 2 days. He also had bilateral pedal edema and lower limb paresthesia. He had been diagnosed to have obstructive sleep apnea (OSA), rheumatic heart disease with mitral stenosis, hypothyroidism, and cholelithiasis. A provisional diagnosis of community-acquired pneumonia (CAP) of the right lower and middle lobe with morbid obesity was made, and he was started on noninvasive ventilation and bilevel positive airway pressure due to the respiratory failure. On the 2 nd day of admission, amoxicillin/ clavulanic acid (intravenous dose, 1.2 g, 8 th hourly) and azithromycin (500 mg, once daily (OD), oral) were started empirically in view of fever and signs of sepsis. Due to continuing respiratory failure, he developed CO 2 narcosis, and in view of a low Glasgow Coma Scale, he was intubated. Electroencephalography showed abnormal recordings with hemispherical dysfunction, following which tracheostomy was done (on day 17 of admission). During his course in the hospital, he developed high-grade fever spikes, thrombophlebitis at the site of central lines, and reduced urine output.
On examination, his temperature was 39°C, pulse rate was 109 beats/min, blood pressure was 154/109 mmHg, and the respiratory rate was 33 breaths/min. His blood samples and endotracheal (ET) aspirates were sent (on day 20 of admission) for the microbiological and cytological analysis. Investigations revealed hemoglobin of 9.2 g/dl, total leukocyte count of 22,300/μl (polymorphs 89%, lymphocytes 4%, eosinophils 7%, and monocytes 1%), with normal platelet, and red blood cell counts and a positive C-reactive protein (183 mg/L). Renal function tests were deranged with blood urea (121 mg/dL) and serum creatinine (1.3 mg/dL). Fasting blood sugar level and liver function tests were within the normal limits. His blood gas analysis report showed FiO 2 of 60%.
On day 28 of hospital admission, his paired blood samples (from both central line and peripheral line) grew Pseudomonas aeruginosa (sensitive isolate) and Candida species. ET aspirate grew MDR Acinetobacter baumannii sensitive only to polymyxin B. The patient was diagnosed to have injury and multisystem organ failure leading to prolonged hospital stay and long-term central venous catheters and MDR P. aeruginosa sepsis.
Most recent cases report similar multiple comorbidities precipitating C. auris infection in patients with a prolonged hospital stay. [1, 5, 9] C. auris is commonly misidentified as C. haemulonii, Candida famata, Candida sake, Rhodotorula glutinis, and Saccharomyces cerevisiae by the conventional systems including API 20C and automated identification systems such as Vitek 2 and Phoenix, which can lead to inadequate treatment and poor outcome. [1, 5, 8, 10] The present isolate grew at 42°C, and the conventional methods of identification were inconclusive. The growth of C. auris on CHROMagar (HiCrome™ Candida differential agar from HiMedia) may be pale purple or pink or white-to-cream-colored smooth colonies or no characteristic colored colonies, which could be due to varied incubatory conditions. On Gram staining, they may appear in single, paired, and/or sometimes, grouped as oval-to-elongate budding cells of varied size without pseudohyphae. [3, 11] The thermoresistance of C. auris that allows it to grow between 30°C and 40°C-42°C and inability to grow on cycloheximide-containing medium may be possibly used as a marker for the identification of this pathogenic yeast. [11, 12] Available options for rapid and accurate identification of C. auris are DNA sequencers or matrix MALDI-TOF biotypers. Two platforms for MALDI-TOF MS are available, namely Bruker Biotyper™ and Vitek MS, which can detect C. auris within few minutes and are 100% sensitive and specific. DNA sequencing also could confirm the identification as described in various other studies. [4, 5, [13] [14] [15] A detailed description of sequenced C. auris by Chakrabarti et al. and Sharma et al. showed that the C. auris genome is different from that of Candida albicans by 99.5% and had the closest homology with the genome of Candida lusitaniae (85.9%-86.4%). [16, 17] Resistance to all three classes of antifungals has been reported in various studies; fluconazole resistance is maximum (up to 90%), voriconazole (50%), amphotericin B (35%), and to echinocandins (2%-8%). [4, 5, 18] It has a very closer phylogenetic relationship with Candida krusei, C. haemulonii, Candida pseudohaemulonii, and C. lusitaniae, which are intrinsically resistant to azoles and amphotericin B. This could be a probable reason for the similarly higher resistance of C. auris to these classes of drugs. [5, 19] A higher rate of resistance to flucytosine and echinocandins (caspofungin, micafungin, and anidulafungin) has been also well-documented. [13, 16] Thus, MDR nonalbicans Candida isolate should be considered as a possible indicator of potential C. auris infection. The optimal therapeutic option for C. auris infections is currently unknown. However, due to relatively low resistance to echinocandins, they can be recommended for the empirical therapy. The management of infections caused by these superbugs should be guided by antifungal susceptibility results. [4, 11, 16] C. auris can be transmitted by multiple modes. Due to its ability to persist on both dry and moist surfaces, floors, sinks, bedding materials, the air, on the skin, and in nasal cavities etc., it colonizes and spreads rapidly in health-care settings and can cause nosocomial outbreaks. [11, 13] Very short contact time of 4 h is sufficient enough for the acquisition of C. auris from a colonized patient, and within 48 h of admission into ICUs, invasive infections have been acquired. [7] C. auris has been associated with a variety of invasive fungal infections. Invasive C. auris infection may range from candidemia (mainly associated with central venous catheter use) to pericarditis, respiratory tract, and urinary tract infections, especially occurs in critically ill patients, as we have found in this case. [7, 9, 11, 16] Health-care workers can also be possible agents of transmission; hence, isolation of the patient as well as contact precaution is necessary. The decontamination of instruments and strict adherence to hand hygiene may play an important role in preventing transmission of this hardy fungus. [1, 7, 15] CONCLUSION C. auris is an emerging MDR pathogen which is a diagnostic challenge in clinical laboratories. Any multi-drug resistant Candida species isolated from blood sample of a critically ill patient with underlying morbidities, which has been difficult to identify by the conventional diagnostic methods, should raise the suspicion of possibility of C.auris infection. Appropriate identification is the key to treat and contain infections caused by this organism. Treatment should be guided by susceptibility reports in consultation with infectious disease specialists. Appropriate infection control measures, including isolation and strict hand hygiene practice, should be instituted to prevent transmission and contain this emerging threat.
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